Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.

Frenck RW Jr, Ervin J, Chu L, Abbanat D, Spiessens B, Go O, Haazen W, van den Dobbelsteen G, Poolman J, Thoelen S, Ibarra de Palacios P.

Lancet Infect Dis. 2019 Jun;19(6):631-640. doi: 10.1016/S1473-3099(18)30803-X. Epub 2019 May 9.

PMID:
31079947
2.

Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.

Queenan AM, Dowling DJ, Cheng WK, Faé K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, Wiertsema S, Fortanier A, van den Dobbelsteen G, Levy O, Poolman J.

Vaccine. 2019 Jan 3;37(1):80-89. doi: 10.1016/j.vaccine.2018.11.028. Epub 2018 Nov 23.

PMID:
30478007
3.

Building teams to create innovative new vaccines.

Poolman J.

Hum Vaccin Immunother. 2018;14(12):2808-2810. doi: 10.1080/21645515.2018.1530523. Epub 2018 Oct 26. No abstract available.

PMID:
30346885
4.

Escherichia coli and Staphylococcus aureus: leading bacterial pathogens of healthcare associated infections and bacteremia in older-age populations.

Poolman JT, Anderson AS.

Expert Rev Vaccines. 2018 Jul;17(7):607-618. doi: 10.1080/14760584.2018.1488590. Epub 2018 Jul 9. Review.

PMID:
29902092
5.

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.

Inoue M, Ogawa T, Tamura H, Hagiwara Y, Saito Y, Abbanat D, van den Dobbelsteen G, Hermans P, Thoelen S, Poolman J, Ibarra de Palacios P.

Hum Vaccin Immunother. 2018;14(9):2150-2157. doi: 10.1080/21645515.2018.1474316. Epub 2018 Jun 28.

6.

Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines.

Zomer A, Otsuka N, Hiramatsu Y, Kamachi K, Nishimura N, Ozaki T, Poolman J, Geurtsen J.

Microb Genom. 2018 May;4(5). doi: 10.1099/mgen.0.000180. Epub 2018 May 17.

7.

Toward an Improved Meningococcal Serogroup B Assay.

Poolman J.

MBio. 2018 May 15;9(3). pii: e00713-18. doi: 10.1128/mBio.00713-18.

8.

Chemical signal activation of an organocatalyst enables control over soft material formation.

Trausel F, Maity C, Poolman JM, Kouwenberg DSJ, Versluis F, van Esch JH, Eelkema R.

Nat Commun. 2017 Oct 12;8(1):879. doi: 10.1038/s41467-017-00998-3.

9.

Development and Qualification of an Opsonophagocytic Killing Assay To Assess Immunogenicity of a Bioconjugated Escherichia coli Vaccine.

Abbanat D, Davies TA, Amsler K, He W, Fae K, Janssen S, Poolman JT, van den Dobbelsteen GPJM.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00123-17. doi: 10.1128/CVI.00123-17. Print 2017 Dec.

10.

Compartmentalizing Supramolecular Hydrogels Using Aqueous Multi-phase Systems.

Mytnyk S, Olive AGL, Versluis F, Poolman JM, Mendes E, Eelkema R, van Esch JH.

Angew Chem Int Ed Engl. 2017 Nov 20;56(47):14923-14927. doi: 10.1002/anie.201706272. Epub 2017 Sep 12.

PMID:
28815916
11.

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.

Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frölich R, Dreyer AM, Martin P, Davies T, Fae K, van den Nieuwenhof I, Thoelen S, de Vallière S, Kuhn A, Bernasconi E, Viereck V, Kavvadias T, Kling K, Ryu G, Hülder T, Gröger S, Scheiner D, Alaimo C, Harbarth S, Poolman J, Fonck VG.

Lancet Infect Dis. 2017 May;17(5):528-537. doi: 10.1016/S1473-3099(17)30108-1. Epub 2017 Feb 24.

PMID:
28238601
12.

Crosslinker-Induced Effects on the Gelation Pathway of a Low Molecular Weight Hydrogel.

Noteborn WE, Zwagerman DN, Talens VS, Maity C, van der Mee L, Poolman JM, Mytnyk S, van Esch JH, Kros A, Eelkema R, Kieltyka RE.

Adv Mater. 2017 Mar;29(12). doi: 10.1002/adma.201603769. Epub 2017 Jan 24.

PMID:
28117500
13.

Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models.

van den Dobbelsteen GPJM, Faé KC, Serroyen J, van den Nieuwenhof IM, Braun M, Haeuptle MA, Sirena D, Schneider J, Alaimo C, Lipowsky G, Gambillara-Fonck V, Wacker M, Poolman JT.

Vaccine. 2016 Jul 29;34(35):4152-4160. doi: 10.1016/j.vaccine.2016.06.067. Epub 2016 Jul 6.

PMID:
27395567
14.

Negatively Charged Lipid Membranes Catalyze Supramolecular Hydrogel Formation.

Versluis F, van Elsland DM, Mytnyk S, Perrier DL, Trausel F, Poolman JM, Maity C, le Sage VA, van Kasteren SI, van Esch JH, Eelkema R.

J Am Chem Soc. 2016 Jul 20;138(28):8670-3. doi: 10.1021/jacs.6b03853. Epub 2016 Jul 7.

PMID:
27359373
15.

Catalysis of Supramolecular Hydrogelation.

Trausel F, Versluis F, Maity C, Poolman JM, Lovrak M, van Esch JH, Eelkema R.

Acc Chem Res. 2016 Jul 19;49(7):1440-7. doi: 10.1021/acs.accounts.6b00137. Epub 2016 Jun 17.

PMID:
27314682
16.

Bordetella pertussis filamentous hemagglutinin itself does not trigger anti-inflammatory interleukin-10 production by human dendritic cells.

Villarino Romero R, Hasan S, Faé K, Holubova J, Geurtsen J, Schwarzer M, Wiertsema S, Osicka R, Poolman J, Sebo P.

Int J Med Microbiol. 2016 Jan;306(1):38-47. doi: 10.1016/j.ijmm.2015.11.003. Epub 2015 Nov 30.

PMID:
26699834
17.

Predicting future trends in the burden of pertussis in the 21st century: implications for infant pertussis and the success of maternal immunization.

van den Biggelaar AH, Poolman JT.

Expert Rev Vaccines. 2016;15(1):69-80. doi: 10.1586/14760584.2016.1105136. Epub 2015 Nov 11. Review.

PMID:
26559122
18.

Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field.

Poolman JT, Wacker M.

J Infect Dis. 2016 Jan 1;213(1):6-13. doi: 10.1093/infdis/jiv429. Epub 2015 Sep 2. Review.

19.

Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness.

Poolman JT, Richmond P.

Expert Rev Vaccines. 2015;14(9):1277-87. doi: 10.1586/14760584.2015.1071670. Epub 2015 Jul 23. Review.

PMID:
26204792
20.

Foreword. Pertussis vaccines.

Poolman JT.

Expert Rev Vaccines. 2014 Sep;13(9):1067-9. doi: 10.1586/14760584.2014.946910. No abstract available.

PMID:
25115214
21.

Shortcomings of pertussis vaccines: why we need a third generation vaccine.

Poolman JT.

Expert Rev Vaccines. 2014 Oct;13(10):1159-62. doi: 10.1586/14760584.2014.944902. Epub 2014 Aug 4.

PMID:
25089373
22.

The mouse intranasal challenge model for potency testing of whole-cell pertussis vaccines.

Queenan AM, Fernandez J, Shang W, Wiertsema S, van den Dobbelsteen GP, Poolman J.

Expert Rev Vaccines. 2014 Oct;13(10):1265-70. doi: 10.1586/14760584.2014.938642. Epub 2014 Jul 17.

PMID:
25029905
23.

Variable gelation time and stiffness of low-molecular-weight hydrogels through catalytic control over self-assembly.

Poolman JM, Boekhoven J, Besselink A, Olive AG, van Esch JH, Eelkema R.

Nat Protoc. 2014 Apr;9(4):977-88. doi: 10.1038/nprot.2014.055. Epub 2014 Mar 27.

PMID:
24675737
24.

Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapelière PG, Verlant V, Vink PE.

Clin Vaccine Immunol. 2014 May;21(5):651-60. doi: 10.1128/CVI.00807-13. Epub 2014 Mar 5.

25.

Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.

Williams JN, Weynants V, Poolman JT, Heckels JE, Christodoulides M.

Vaccine. 2014 Mar 5;32(11):1280-6. doi: 10.1016/j.vaccine.2013.12.070. Epub 2014 Jan 30.

PMID:
24486354
26.

Zinc piracy as a mechanism of Neisseria meningitidis for evasion of nutritional immunity.

Stork M, Grijpstra J, Bos MP, Mañas Torres C, Devos N, Poolman JT, Chazin WJ, Tommassen J.

PLoS Pathog. 2013 Oct;9(10):e1003733. doi: 10.1371/journal.ppat.1003733. Epub 2013 Oct 31.

27.

The history of pneumococcal conjugate vaccine development: dose selection.

Poolman JT, Peeters CC, van den Dobbelsteen GP.

Expert Rev Vaccines. 2013 Dec;12(12):1379-94. doi: 10.1586/14760584.2013.852475. Review.

PMID:
24195479
28.

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.

Leroux-Roels I, Devaster JM, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, Hermand P, Van Belle P, Poolman JT, Vandepapelière P, Horsmans Y.

Vaccine. 2015 Jan 15;33(4):577-84. doi: 10.1016/j.vaccine.2013.10.052. Epub 2013 Oct 29.

29.

Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.

Peak IR, Srikhanta YN, Weynants VE, Feron C, Poolman JT, Jennings MP.

PLoS One. 2013 Sep 6;8(9):e72003. doi: 10.1371/journal.pone.0072003. eCollection 2013.

30.

Unbiased tracking of the progression of mRNA and protein synthesis in bulk and in liposome-confined reactions.

van Nies P, Nourian Z, Kok M, van Wijk R, Moeskops J, Westerlaken I, Poolman JM, Eelkema R, van Esch JH, Kuruma Y, Ueda T, Danelon C.

Chembiochem. 2013 Oct 11;14(15):1963-6. doi: 10.1002/cbic.201300449. Epub 2013 Sep 11.

PMID:
24027226
31.

Description and nomenclature of Neisseria meningitidis capsule locus.

Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, Bentley SD, Maiden MC.

Emerg Infect Dis. 2013 Apr;19(4):566-73. doi: 10.3201/eid1904.111799.

32.

Catalytic control over supramolecular gel formation.

Boekhoven J, Poolman JM, Maity C, Li F, van der Mee L, Minkenberg CB, Mendes E, van Esch JH, Eelkema R.

Nat Chem. 2013 May;5(5):433-7. doi: 10.1038/nchem.1617. Epub 2013 Apr 7.

PMID:
23609096
33.

ZnuD, a potential candidate for a simple and universal Neisseria meningitidis vaccine.

Hubert K, Devos N, Mordhorst I, Tans C, Baudoux G, Feron C, Goraj K, Tommassen J, Vogel U, Poolman JT, Weynants V.

Infect Immun. 2013 Jun;81(6):1915-27. doi: 10.1128/IAI.01312-12. Epub 2013 Mar 18.

34.

Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression.

Devos N, Tans C, Momin P, Plisnier M, Weynants V, Feron C, Poolman JT.

Microbes Infect. 2012 Sep;14(11):979-88. doi: 10.1016/j.micinf.2012.04.005. Epub 2012 Apr 20.

PMID:
22565133
35.

Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance.

Griffiths NJ, Hill DJ, Borodina E, Sessions RB, Devos NI, Feron CM, Poolman JT, Virji M.

Mol Microbiol. 2011 Dec;82(5):1129-49. doi: 10.1111/j.1365-2958.2011.07876.x. Epub 2011 Nov 4.

36.

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

Borrow R, Dagan R, Zepp F, Hallander H, Poolman J.

Expert Rev Vaccines. 2011 Nov;10(11):1621-31. doi: 10.1586/erv.11.142. Review.

PMID:
22043960
37.

Pertussis vaccines: where to now?

Poolman JT, Hallander H, Halperin SA.

Expert Rev Vaccines. 2011 Nov;10(11):1497-500. doi: 10.1586/erv.11.147. No abstract available.

PMID:
22043947
38.
39.

A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.

Denoël P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT.

Vaccine. 2011 Jul 26;29(33):5495-501. doi: 10.1016/j.vaccine.2011.05.051. Epub 2011 May 30.

40.

Meningococcal serogroup B vaccines: will they live up to expectations?

Zollinger WD, Poolman JT, Maiden MC.

Expert Rev Vaccines. 2011 May;10(5):559-61. doi: 10.1586/erv.11.41. No abstract available.

41.

Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.

Poolman JT, De Vleeschauwer I, Durant N, Devos N, Feron C, Lestrate P, Weynants V, Boutriau D.

Clin Vaccine Immunol. 2011 Jul;18(7):1108-17. doi: 10.1128/CVI.00549-10. Epub 2011 May 18.

42.

Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines.

Poolman J, Borrow R.

Expert Rev Vaccines. 2011 Mar;10(3):307-22. doi: 10.1586/erv.11.8. Review.

PMID:
21434799
43.

Induction of Bordetella pertussis-specific immune memory by DTPa vaccines.

Morel S, Denoël P, Godfroid F, Cortvrindt C, Vanderheyde N, Poolman J.

Vaccine. 2011 Apr 18;29(18):3449-55. doi: 10.1016/j.vaccine.2011.02.062. Epub 2011 Mar 5.

PMID:
21382483
44.

Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides.

Denoël P, Godfroid F, Hermand P, Verlant V, Poolman J.

Vaccine. 2011 Sep 2;29(38):6451-3. doi: 10.1016/j.vaccine.2011.01.085. Epub 2011 Feb 11.

PMID:
21315695
45.

Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study.

Leendertse AJ, Van Den Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ.

Value Health. 2011 Jan;14(1):34-40. doi: 10.1016/j.jval.2010.10.024.

46.

Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media.

Johnson RW, McGillivary G, Denoël P, Poolman J, Bakaletz LO.

Vaccine. 2011 Feb 1;29(6):1211-21. doi: 10.1016/j.vaccine.2010.12.003. Epub 2010 Dec 16.

PMID:
21167861
47.

Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.

Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L.

Clin Vaccine Immunol. 2011 Feb;18(2):327-36. doi: 10.1128/CVI.00402-10. Epub 2010 Dec 1.

48.

Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera.

Rose CE, Romero-Steiner S, Burton RL, Carlone GM, Goldblatt D, Nahm MH, Ashton L, Haston M, Ekström N, Haikala R, Käyhty H, Henckaerts I, Durant N, Poolman JT, Fernsten P, Yu X, Hu BT, Jansen KU, Blake M, Simonetti ER, Hermans PW, Plikaytis BD.

Clin Vaccine Immunol. 2011 Jan;18(1):135-42. doi: 10.1128/CVI.00370-10. Epub 2010 Nov 17.

49.

Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae.

Rioux S, Neyt C, Di Paolo E, Turpin L, Charland N, Labbé S, Mortier MC, Mitchell TJ, Feron C, Martin D, Poolman JT.

Microbiology. 2011 Feb;157(Pt 2):336-48. doi: 10.1099/mic.0.042184-0. Epub 2010 Oct 21.

PMID:
20966093
50.

Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens.

Godfroid F, Hermand P, Verlant V, Denoël P, Poolman JT.

Infect Immun. 2011 Jan;79(1):238-45. doi: 10.1128/IAI.00378-10. Epub 2010 Oct 18.

Supplemental Content

Loading ...
Support Center